RESUMEN
OBJECTIVE: To find the association between hyperuricemia and ischemic stroke. STUDY DESIGN: Case-control study. PLACE AND DURATION OF STUDY: Departments of Medicine and Neurology, Mayo Hospital, Lahore, from October 2015 to September 2016. METHODOLOGY: A total of 100 patients were recruited in the study. Fifty cases were of acute ischemic stroke and fifty were age- and gender-matched healthy controls. Serum uric acid level was estimted by photometry method at the time of admission. Hyperuricemia was defined as the serum uric acid level of more than 6 mg/dl. RESULTS: Mean serum uric acid levels in cases and controls were 5.996 ±1.99 mg/dl and 5.042 ±0.91 mg/dl, respectively. Hyperuricemia was present in 23 (46%) patients with ischemic stroke and in 10 (20%) controls. Among ischemic stroke patients, the frequency of hyperuricemia was significantly higher than in controls (p-value =0.006, Odds Ratio (OR) =3.41.) Conclusion: Serum uric acid was found significantly elevated in ischemic stroke patients versus controls with 3.41 times more risk of having hyperuricemia in ischemic stroke patients. Key Words: Hyperuricemia, Ischemic stroke, Serum uric acid (SUA).
Asunto(s)
Isquemia Encefálica , Hiperuricemia , Accidente Cerebrovascular Isquémico , Accidente Cerebrovascular , Isquemia Encefálica/epidemiología , Isquemia Encefálica/etiología , Estudios de Casos y Controles , Humanos , Hiperuricemia/complicaciones , Hiperuricemia/epidemiología , Factores de Riesgo , Accidente Cerebrovascular/epidemiología , Ácido ÚricoRESUMEN
Direct infusion high-resolution mass spectrometry (DIHRMS) is a novel, high-throughput approach to rapidly and accurately profile hundreds of lipids in human serum without prior chromatography, facilitating in-depth lipid phenotyping for large epidemiological studies to reveal the detailed associations of individual lipids with coronary heart disease (CHD) risk factors. Intact lipid profiling by DIHRMS was performed on 5662 serum samples from healthy participants in the Pakistan Risk of Myocardial Infarction Study (PROMIS). We developed a novel semi-targeted peak-picking algorithm to detect mass-to-charge ratios in positive and negative ionization modes. We analyzed lipid partial correlations, assessed the association of lipid principal components with established CHD risk factors and genetic variants, and examined differences between lipids for a common genetic polymorphism. The DIHRMS method provided information on 360 lipids (including fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, and sterol lipids), with a median coefficient of variation of 11.6% (range: 5.4-51.9). The lipids were highly correlated and exhibited a range of associations with clinical chemistry biomarkers and lifestyle factors. This platform can provide many novel insights into the effects of physiology and lifestyle on lipid metabolism, genetic determinants of lipids, and the relationship between individual lipids and CHD risk factors.
Asunto(s)
Biomarcadores/sangre , Enfermedad Coronaria/genética , Lípidos/genética , Enfermedad Coronaria/sangre , Enfermedad Coronaria/patología , Femenino , Variación Genética , Glicerofosfolípidos/sangre , Humanos , Metabolismo de los Lípidos/genética , Lípidos/sangre , Masculino , Persona de Mediana Edad , Factores de Riesgo , Esfingolípidos/sangre , Esfingolípidos/genética , Esteroles/sangreRESUMEN
To evaluate the shared genetic etiology of type 2 diabetes (T2D) and coronary heart disease (CHD), we conducted a genome-wide, multi-ancestry study of genetic variation for both diseases in up to 265,678 subjects for T2D and 260,365 subjects for CHD. We identify 16 previously unreported loci for T2D and 1 locus for CHD, including a new T2D association at a missense variant in HLA-DRB5 (odds ratio (OR) = 1.29). We show that genetically mediated increase in T2D risk also confers higher CHD risk. Joint T2D-CHD analysis identified eight variants-two of which are coding-where T2D and CHD associations appear to colocalize, including a new joint T2D-CHD association at the CCDC92 locus that also replicated for T2D. The variants associated with both outcomes implicate new pathways as well as targets of existing drugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.
Asunto(s)
Enfermedad Coronaria/genética , Diabetes Mellitus Tipo 2/genética , Estudio de Asociación del Genoma Completo , Asia/epidemiología , Pueblo Asiatico/genética , Biomarcadores , Comorbilidad , Enfermedad Coronaria/epidemiología , Enfermedad Coronaria/etiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/etiología , Europa (Continente)/epidemiología , Sitios Genéticos/genética , Predisposición Genética a la Enfermedad , Cadenas HLA-DRB5/genética , Humanos , Redes y Vías Metabólicas/genética , Síndrome Metabólico/epidemiología , Síndrome Metabólico/genética , Terapia Molecular Dirigida , Mutación Missense , Polimorfismo de Nucleótido Simple , Factores de Riesgo , Población Blanca/genéticaRESUMEN
Isolated hepatic tuberculosis without pulmonary or bowel involvement is a diagnostic challenge and can cause considerable morbidity. A young lady from Lahore presented with fever, pain in right hypochondria, nausea and weight loss. CT scan of abdomen showed multiple small hypodense non-enhancing lesions and a heterogeneous texture of liver. Biopsy confirmed the diagnosis of hepatic tuberculosis. It was concluded a case of isolated hepatic tuberculosis without evidence of other primary sites involvement. It is important to consider tuberculosis in the differential diagnosis when suspecting lymphoproliferative or metastatic diseases in a patient with vague symptoms and abnormal hepatic texture on CT.
